HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

This article was originally published in The Tan Sheet

Executive Summary

Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.

You may also be interested in...



Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth

Following allegations from short seller Citron Research that it operates a “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.

Mibelle Looks To Maintain Momentum In Plant Stem Cells

Mibelle’s R&D team has been working to expand the company’s actives portfolio and capitalize on the popularity of plant stem cells that can fend off the signs of aging.

Universe Of Skin Care Targeting Stem Cells, DNA Continues To Grow

More anti-aging solutions are reaching market with claims to stimulate stem cells in skin and protect or even repair DNA. Makucell, E’shee and Terraternal add new offerings to the mix.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel